Table 5. The efficacy of Bismuth plus Furazolidone- or Clarithromycin-containing quadruple therapies for H. pylori eradication .

Year	City	Therapy	Treatment duration (days)	Number of patients.	Underlying disease	Eradication assessment method.	Duration from therapy (week)	Per-protocol eradication rate
2007	Isfahan50	OABF	7	78	H. pylori (+)	UBT	4	84.8
2010	Tehran28	OABM-F OABC-F	10 (M: 5, F: 5, C: 5)	103 103	PUD	UBT	8	91.3 88.7
2015	Sari38	OABF OABM-F	10 (M: 5, F: 5)	120 120	PUD	UBT	8	86.6 82.5
2000	Tehran46	RABF	14	53	DU	UBT	4	82
2001	Tehran51	OABF	14	63	DU	UBT	12	90
2004	Sari40	OABF (F: 100 BID) OABF (F: 200 BID)	14 14	50 50	DU	UBT	12	72 92
2007	Isfahan50	OABF	14	78	H. pylori (+)	UBT	4	82.6
2007	Tehran45	OABF OABF-M	14 (F: 7, M: 7)	104 103	PUD	UBT	8	95.2 95.3
2009	Shiraz34	OABF	14	69	H. pylori (+)	UBT	4-6	56
2011	Ghom41	OABF	14	43	H. pylori (+)	UBT	12	85.3
2012	Sari40	OABF	14 (F: 7)	80	PUD	UBT	12	90.2
2012	Sari56	OABF	14 (F: 7)	124	PUD	UBT	8	88.7
2015	Tehran53	OABC	10	60	H. pylori (+)	UBT	8	65.2
2001	Tehran49	OBCT (C: 250 BID)	14	73	DU	UBT	8	88
2001	Tehran51	OABC	14	55	DU	UBT	12	90
2013	Isfahan54	OABC OABC + probiotic	14	90	PUD	UBT	4	82.1 84.4

O: Omeprazole, R: Ranitidine, Amox: Amoxicillin, B: Bismuth subcitrate, Tetra: Tetracycline, M: Metronidazole, C: Clarithromycin, F: Furazolidone, DU: Duodenal ulcer, PUD: Peptic ulcer disease, UBT: Urea breath test, BID: twice daily